Medique Medicidin D

Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hydrochloride


Unifirst First Aid Corporation
Human Otc Drug
NDC 47682-120
Medique Medicidin D also known as Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hydrochloride is a human otc drug labeled by 'Unifirst First Aid Corporation'. National Drug Code (NDC) number for Medique Medicidin D is 47682-120. This drug is available in dosage form of Tablet, Film Coated. The names of the active, medicinal ingredients in Medique Medicidin D drug includes Acetaminophen - 325 mg/1 Chlorpheniramine Maleate - 2 mg/1 Phenylephrine Hydrochloride - 5 mg/1 . The currest status of Medique Medicidin D drug is Active.

Drug Information:

Drug NDC: 47682-120
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Medique Medicidin D
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hydrochloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Unifirst First Aid Corporation
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet, Film Coated
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ACETAMINOPHEN - 325 mg/1
CHLORPHENIRAMINE MALEATE - 2 mg/1
PHENYLEPHRINE HYDROCHLORIDE - 5 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 30 Dec, 2008
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 07 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part341
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Unifirst First Aid Corporation
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1046781
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:362O9ITL9D
04JA59TNSJ
V1Q0O9OJ9Z
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Adrenergic alpha1-Agonists [MoA]
Histamine H1 Receptor Antagonists [MoA]
Histamine-1 Receptor Antagonist [EPC]
alpha-1 Adrenergic Agonist [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
47682-120-13250 PACKET in 1 BOX (47682-120-13) / 2 TABLET, FILM COATED in 1 PACKET (47682-120-99)30 Dec, 2008N/ANo
47682-120-3350 PACKET in 1 BOX (47682-120-33) / 2 TABLET, FILM COATED in 1 PACKET30 Dec, 2008N/ANo
47682-120-47100 PACKET in 1 BOX (47682-120-47) / 2 TABLET, FILM COATED in 1 PACKET30 Dec, 2008N/ANo
47682-120-6412 PACKET in 1 BOX (47682-120-64) / 2 TABLET, FILM COATED in 1 PACKET30 Dec, 2008N/ANo
47682-120-992 TABLET, FILM COATED in 1 PACKET (47682-120-99)30 Dec, 2008N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose pain reliever/fever reducer antihistamine nasal decongestant

Product Elements:

Otis clapp valihist acetaminophen,chlorpheniramine maleate, phenylephrine hydrochloride cellulose, microcrystalline hypromelloses polyethylene glycol, unspecified starch, corn stearic acid crospovidone povidone acetaminophen acetaminophen chlorpheniramine maleate chlorpheniramine phenylephrine hydrochloride phenylephrine white round az;275 medique medicidin d acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride cellulose, microcrystalline hypromelloses polyethylene glycol, unspecified starch, corn stearic acid crospovidone povidone acetaminophen acetaminophen chlorpheniramine maleate chlorpheniramine phenylephrine hydrochloride phenylephrine white round az;275

Indications and Usage:

Uses temporarily relieves minor aches and pains headache nasal congestion sinus congestion and pressure runny nose sneezing temporarily reduces fever relieves runny nose and reduces sneezing, itching of the nose and throat and itchy, watery eyes due to hay fever helps clear nasal and/or sinus passages

Warnings:

Warnings liver warning: this product contains acetaminophen. severe liver damage may occur if you take: more than 4,000 mg of acetaminophen in 24 hours, which is the maximum daily amount with other drugs containing acetaminophen 3 or more alcoholic drinks every day while using this product allergy alert: acetaminophen may cause severe skin reactions. symptoms may include: skin reddening blisters rash if a skin reaction occurs, stop use and seek medical help right away.

Do Not Use:

Warnings liver warning: this product contains acetaminophen. severe liver damage may occur if you take: more than 4,000 mg of acetaminophen in 24 hours, which is the maximum daily amount with other drugs containing acetaminophen 3 or more alcoholic drinks every day while using this product allergy alert: acetaminophen may cause severe skin reactions. symptoms may include: skin reddening blisters rash if a skin reaction occurs, stop use and seek medical help right away.

When Using:

When using this product do not exceed recommended dosage excitability may occur, especially in children may cause drowsiness alcohol, sedatives and tranquilizers may increase drowsiness avoid alcoholic beverages use caution when driving a motor vehicle or operating machinery

Dosage and Administration:

Directions do not use more than directed ​adults and children (12 years and older): take 2 tablets every 4 to 6 hours. do not take more than 10 tablets in 24 hours. children under 12 years: ask a doctor

Stop Use:

Stop use and ask a doctor if nervousness, dizziness or sleeplessness occur pain or nasal congestion gets worse or lasts more than 7 days fever gets worse or lasts more than 3 days redness or swelling is present new symptoms occur if pregnant or breast-feeding , ask a health professional before use.

Package Label Principal Display Panel:

Principal display panel - otis clapp valihist label otis clapp quality and integrity since 1840 valihist ™ decongestant-antihistamine pain reliever-fever reducer antihistamine- decongestant for allergies, colds, runny nose see warnings and directions on side panel this package is for households without young children. acetaminophen 325 mg, chlorpheniramine maleate 2mg phenylephrine hcl 5 mg tear out along perforation to dispense professional healthcare 300 tablets (150 packets of 2) otis

Principal display panel - medique medicidin d label medique® medicidin-d cold and allergy relief this package is for households without young children. pull to open pain reliever/ fever reducer ● acetaminophen 325mg antihistamine ● chlorpheniramine maleate 2mg nasal decongestant ● phenylephrine hcl 5mg 100tablets (50 x 2) tamper evident unit dose packets medique

Further Questions:

Questions or comments? 1-800-634-7680


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.